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 Diabetes Mellitus is a commonly known disease in the United States. Over eight 
percent of the population has the disease, and close to another twenty percent are 
considered pre-diabetic and are susceptible to acquiring the disease in the future. 
Diabetes is dangerous not solely because of the symptoms it presents, but also because of 
the associated diseases (such as cardiovascular disease) linked to diabetic patients. The 
first chapter of this thesis outlines the disease, indicating the pathogenesis, symptoms, 
diagnosis, treatment, genetics, and epidemiology. The second chapter provides a 
literature review of a possible mechanism that causes insulin resistance. Tumor Necrosis 
Factor –α is a molecule believed to phosphorylate and inactivate another molecule, 
Insulin Receptor Substrate-1. The specificities of this mechanism are further elucidated 
through experimental data. The third chapter is a case study that highlights a clinical visit 
from a patient presenting with symptoms of Type II Diabetes Mellitus. The case study 
includes common information typically gathered by a physician during a patient visit, 
such as the patient history, physical exam, and diagnostic work, and includes the 
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A Review of the Clinical Features and Pathogenesis of Diabetes Mellitus 
Section Overview: 
 Diabetes Mellitus is one of the most widespread and prominent diseases in the 
country today—close to 26 million people, 8.3% of the population, have been diagnosed 
with the disease (“Diabetes Data”, 2013). Diabetes is a non-communicable disease 
(NCD), meaning that the disease cannot be spread from one person to the next, and there 
are two prevalent forms: type 1 and type 2 (Zimmet, Alberti, & Shaw, 2001). Type 1 is 
due to auto-immune mediated destruction of pancreatic β cells, which results in insulin 
deficiency within the body (Zimmet, Alberti, & Shaw, 2001). Type 2, which is much 
more prevalent with over 90% of current cases within the country, is caused by a 
combination of insulin resistance and impaired insulin secretion. Type 2 diabetes has 
been closely linked to obesity, which has been spurred by an increasingly sedentary 
lifestyle found in developing and already developed countries. Type 2 diabetes is often 
the byproduct of the broadly defined metabolic syndrome and can be associated with 
poor cardiovascular health as well (Zimmet, Alberti, & Shaw, 2001). Diabetes plays a 
prominent role in healthcare today because of its extremely high prevalence within the 
population. Especially with almost 80 million Americans categorized as pre-diabetic 
(“Diabetes Data”, 2013) (indicating high probability of acquiring type 2 diabetes in the 
near future), it is evident that research for diabetic cures and prevention of sedentary and 







 Insulin is a small peptide hormone which is typically released from the pancreas 
by β cells (Zimmet, Alberti, & Shaw, 2001). Insulin release is a response to an increase in 
blood glucose levels. Normally, as glucose enters through Glut-2 molecules of the 
pancreas, insulin is released (Salway, 2004). As the insulin binds to insulin receptors on 
target cell surfaces, Glut-4 receptors translocate to the plasma membrane and allow for 
facilitated diffusion of glucose molecules down the concentration gradient from blood to 
target (mostly adipose/muscle) cells (Salway, 2004).  
 There are two current hypotheses as to how insulin stimulation promotes glucose 
uptake by Glut-4 receptors. One is the CAP/Cbl hypothesis, where the binding of insulin 
to the insulin receptor causes the receptor to become autophosphorylated, attracting 
associated protein substrate (APS) to the cell membrane to become phosphorylated as 
well. This attracts the protein Cb1, which binds to Cb1-associated protein (CAP). This 
binds to a GDP/GTP exchange protein, and as GDP is replaced with GTP, Glut-4 
containing vesicles are propelled toward the plasma membrane. Upon arrival at the 
membrane, SNARE proteins bind to the target SNARE complex, and Glut-4 proteins are 
inserted into the membrane to allow uptake of glucose by the cell (Salway, 2004). 
 The other mechanism involves phosphorylating Insulin Receptor Substrate-1 
(IRS-1), which attracts and binds to phosphotidylinositol-3 kinase to form a complex, 
which binds to protein kinase B (PKB) and  phosphoinositide-dependent kinase 1 (PKD-
1). This binding causes PKB to become activated; PKB phosphorylates proteins involved 
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in Glut-4 translocation to the cell membrane, and also inactivates glycogen synthase 
kinase-3 (GSK-3), allowing glycogen synthesis to occur (Salway, 2004). 
 In type 1 diabetes, pancreatic β cells do not produce or secrete insulin. Metabolic 
homeostasis is disrupted when insulin is not available, so some of the symptoms of 
metabolic syndrome result. Typically, fatty acids released by adipose tissue after lipolysis 
are re-esterified and reformed into triacylglycerol (TAG) through the molecule glycerol-
3-phosphate. However, glycerol-3-phosphate is not available in the diabetic case because 
it is formed from glucose, which is not readily available in diabetic cells. Because fatty 
acids cannot be re-esterified, they are released into the blood instead as free fatty acids 
(FFA), which results in the symptom called dyslipidemia often found with diabetic 
patients. Fatty acids can generally be oxidized as fuel, but in diabetic patients, there is so 
much FFA that it is transported to the liver to undergo beta-oxidation and become 
converted to acetyl CoA. Acetyl CoA is not oxidized well in the Krebs cycle in diabetic 
patients and is instead combined with each other to create ketone bodies. Formation of 
ketone bodies may be associated with the formation of acetoacetic acid and D-3-
hydroxybutyric acid, which causes pH buffering in the body to go awry and causes keto-
acidosis in severe cases (Salway, 2004). 
 Type 2 diabetes is usually a result of both defective insulin secretion and 
resistance to insulin action. Secretion of insulin from pancreatic beta cells might be 
inadequate or insufficient to uptake all of the glucose that enters the blood stream after a 
large carbohydrate meal. Especially with current unhealthy eating habits in the United 
States when individuals have starch and sugar-filled meals (such as meals found in fast 
food) coupled with a sedentary lifestyle where that glucose is not burned off readily, 
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glucose “sits” in the blood stream and the body’s typical insulin production is not 
sufficient to uptake all of that glucose. Rarely, type 2 diabetes results because the insulin 
released through beta cells are structurally abnormal. Thus, the insulin can only be 
partially functional, so blood glucose cannot be as easily or as readily absorbed. The 
defect could be in the tissue targeted by the insulin as well. The insulin receptor could be 
structurally defective, or transduction and amplification of the insulin signal to 
intracellular metabolic processes could be impaired. Gene expression or phosphorylation 
for proteins and enzymes important for glucose mediation could also be impaired, which 
would also lead to glucose imbalance and eventual diabetes (Salway, 2004). 
Clinical Features and Diagnosis 
Diabetes is typically diagnosed through the presence of high blood glucose levels. 
The American Diabetic Association (ADA) recommends that diabetes be clinically 
diagnosed when blood glucose tests show more than 126 mg glucose/dL of blood after 
the patient has fasted for 8 hours, or if blood glucose levels are above 200 mg/dL at any 
point, even after meals (“Diabetes Care”, 2013).  
Clinicians are sometimes hesitant to use blood glucose tests because they measure 
blood glucose levels only at that moment in time—it is very possible for a patient with 
typical hyperglycemia to have an abnormally low reading when tested at the clinic, which 
would result in their diabetic symptoms going unnoticed. The hemoglobin A1C test is 
more accurate in that it reflects the patient’s average blood glucose levels over a three 
month time span (“A1C Test”, 2013). Hemoglobin found in erythrocytes glycates with 
glucose found in the blood. The A1C is a reflection of the percentage of hemoglobin that 
is glycated. A1C levels can be written as eAG or “average glucose” levels, which 
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corresponds A1C percentages to blood glucose levels. An A1C level above 6.5% is 
concerning because it correlates to blood glucose levels of above 126 mg/dL (“A1C 
Test”, 2013). 
Another test for blood glucose levels is the Oral Glucose Tolerance Test 
(“Glucose Tolerance”, 2013). This test is performed especially for patients experiencing 
gestational diabetes—this type of diabetes is neither type 1 nor type 2, and occurs in 
female patients only during pregnancy. Once the pregnancy comes to term, the patient’s 
glycemic levels return to normal. To perform this test, the patient first drinks fluids 
dissolved with 75 grams of glucose. Two hours after ingestion, if the patient’s blood 
glucose levels are above 200 mg/dL, this is indicative of diabetes. A Blood glucose level 
between 140-200 mg/dL is considered impaired glucose tolerance and should also be 
monitored (“Glucose Tolerance”, 2013). 
Patients can also be diagnosed as pre-diabetic. This indicates that the patient does 
not have blood glucose levels high enough to be clinically diagnosed as diabetic, yet still 
has elevated blood glucose levels and impaired glucose tolerance (“Diabetes Care”, 
2013). The patient presents certain risks associated with diabetes, including the 
development of diabetic symptoms as well as the development of metabolic syndrome 
and cardiovascular disease. Pre-diabetes is typically agreed upon as blood glucose levels 
measured between 101-125 mg/dL blood glucose (“Diabetes Care”, 2013). 
Symptoms: 
 Although diabetes is diagnosed mostly through blood glucose testing, there are 
typical symptoms that most diabetic patients present with that can be indicative of the 
disease. For type 1 diabetes, these symptoms include polydipsia (extreme thirst), polyuria 
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(frequent urination), drowsiness, lethargy, sudden vision changes, sudden weight loss, 
heavy and labored breathing, and stupor or unconsciousness (“Diabetes Care”, 2013; 
“Symptoms”, 2013; “Diabetes Symptoms”, 2013). There is also the famous symptom of 
finding sugar in the urine or sweet tasting urine. This is because as glucose exists in the 
blood and is not taken up by host cells, the glucose becomes unused and is excreted as 
waste product (“Diabetes Care”, 2013). 
 Sudden vision changes are a common symptom since diabetes is often associated 
with eye health (“Diabetes Symptoms”, 2013). Diabetic retinopathy is common in 
diabetic patients—the blood vessels in the retina become damaged with increasing blood 
sugar, which leads to blurred vision and eventual blindness (“Facts about Diabetic”, 
2012). Diabetes can lead to the swelling of the lens as well, which also contributes to the 
blurred vision as well as pain or pressure in both eyes. If untreated, diabetes can create 
serious symptoms such as glaucoma and cataracts (“Facts about Diabetic”, 2012). Weight 
loss occurs because as insulin is not frequently produced in type 1 diabetes, the fat 
storage abilities of insulin are reduced and fats that are already stored within the body are 
catabolized (“Diabetes Care”, 2013). 
 Patients with type 2 diabetes present with many of the same symptoms as type 1, 
except signs of weight loss are not very typical. Other symptoms presented by type 2 
patients include slow healing sores and frequent infections, areas of darkened skin, and 
tightening and numbness in the extremities (hands and feet). Symptoms for type 2 
diabetes can be milder than symptoms for type 1, but this is dependent on the progression 





 Diabetes is very widespread within the United States. As mentioned earlier, 25.8 
million people have either type 1 or type 2 diabetes, accounting for 8.3% of the total 
population. Surprisingly, it is estimated that only 18.8 million people have been 
diagnosed (“Diabetes Statistics”, 2013). The 7 million not diagnosed are overwhelmingly 
those who cannot afford or do not have the means to be seen by a physician to get the 
diagnosis. This patient group (those with low income and inability to access healthcare) is 
at a greater risk to develop diabetes and obesity (Zimmet, Alberti, & Shaw, 2001) because 
of lifestyle choices and the inability to have the diabetes prevented and monitored 
through healthcare. 
 Diabetes is more likely to affect individuals in older age groups. The prevalence 
for individuals between the ages of 0 and 20 was 0.26%, whereas the prevalence between 
ages 20 through 65 jumps to 11.3%. The prevalence after the age of 65 climbs even more, 
to 26.9% of that age group—thus, more than 1 in 4 senior citizens has diabetes. Men aged 
20 or older are slightly more likely to have diabetes than women, at 11.8% compared to 
10.8%. African Americans most commonly develop the disease at 12.6%, whereas non-
Hispanic Whites have it least often at 7.1% (“Diabetes Statistics”, 2013). 
 In terms of complications, diabetes is the leading cause of blindness for people 
aged 20-74, with 28.5% of diabetic individuals aged 40 or older developing retinopathy. 
Diabetes is also the leading cause of kidney failure, accounting for 44% of new cases in 
2008. Because untreated diabetes can lead to gangrene (extensive tissue death), many 
diabetic patients have limb removals. It is no surprise then that 60% of non-traumatic 
lower limb amputations occurred because of complications with diabetes. There is also 
8 
 
high correlation between diabetes and cardiovascular disease, with 68% of diabetic 
deaths resulting from heart disease and 67% of diabetic patients experiencing high blood 
pressure (“Diabetes Statistics”, 2013). 
Genetics: 
 Genetic factors play an important role in type 1 and type 2 diabetes, although 
genetics and disease manifestation seem to have a stronger correlation in type 2 
(“Genetics of Diabetes”, 2013). HLA-DR3 and HLA-DR4 seem to play an important role 
in genetically transferred type 1 diabetes, where carrying these genes increases the 
chance of acquiring diabetes. The gene HLA-DR7 has a correlation between African 
Americans and risk for developing diabetes, whereas HLA-DR9 correlates Japanese with 
this risk. For type 2 diabetes, there is a trend that if the parent develops the disease at a 
younger age, their children will have a higher probability of also acquiring it. Moreover, 
the likelihood that a child will develop the disease if both parents have already acquired it 
is increased dramatically. Whereas the likelihood of a man with diabetes having children 
with diabetes is 17:1 and a woman with diabetes with an affected child is 25:1, the 
likelihood of the child having diabetes if both parents are affected is as great as 4:1 
(“Genetics of Diabetes”, 2013).  
 Maturity-onset diabetes of the young (MODY) is an unusual form of diabetes 
characterized by impaired glucose-stimulated insulin secretion by beta cells (Salway, 
2004). This results in hyperglycemia (high blood sugar) but there is no insulin resistance. 




 Other defects that result in abnormal β cell metabolism include defects with the 
glucose transporter Glut-2, which results is glycogen storage disease type XI and 
heterozygous mutations in the genes activating glucokinase, which results in persistent 
hyperinsulinemic hypoglycemia of infancy (PHHI). There are a few mutations that occur 
with the potassium inwardly rectifying chanel (Kir6.2) which is a part of the β cell ATP 
sensitive channel. These mutations also result in PHHI. Peroxisome proliferator activated 
receptor γ (PPAR- γ) is a transcription factor that has a crucial role in adipocyte 
differentiation. Mutations with this receptor can also lead to severe insulin resistance and 
type 2 diabetes (Salway, 2004). 
Environmental Factors: 
 There seems to be a correlation between cold weather and type 1 diabetes 
(“Genetics of Diabetes”, 2013). Type 1 diabetes is more likely to develop in colder 
months of the year (winter) than during the warmer months, and type 1 diabetes has been 
more prevalent in countries with colder climates than in warmer countries. The 
correlation between cold weather and diabetes acquisition is something that has not yet 
been completely understood by scientists; it is hypothesized that hemoglobin in red blood 
cells glycate with higher affinity to glucose during colder temperatures than in warmer 
temperatures (“Genetics of Diabetes”, 2013). 
 Research also shows that viruses may be triggers for type 1 diabetes acquisition 
(Fillippi & von Herrath, 2008). Viruses may illicit auto-immune responses that attack the 
pancreatic β cell and prevent insulin production. Pancreatic islet cells may be infiltrated 
by CD8 T cells and B cells, as well as macrophages and dendritic cells that attack and 
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engulf the β cell. The mechanism and the reason why pancreatic islet cells are solely 
targeted is still being researched (Fillippi & von Herrath, 2008).  
Treatment: 
Insulin deficiency in type 1 diabetics can best be treated with intake of non-native 
commercial insulin (“Diabetes Care”, 2013). Type 1 diabetics take daily insulin 
injections—these injections are measured in IUs (international units) and the amount of 
insulin required is dependent on how much the patient’s blood glucose levels fluctuated 
from normal. Commercial insulin, which was originally harvested from other mammals 
such as pigs and cattle, is now most commonly obtained through DNA recombination 
techniques (Brar, 2007). The gene encoding human insulin is inserted into bacterial DNA 
and cloned to mass produce this non-native insulin (Brar, 2007). Insulin injections can 
also be given to type 2 patients to control insulin on a short term basis (“Diabetes Care”, 
2013). 
Blood glucose “reducing” drugs exist as well (“What I Need”, 2013). These drugs 
work in a myriad of different mechanisms—one of the most popular, Metformin, acts 
through suppression of glucose synthesis in the liver. Thus, the only glucose present in 
the blood would be from food intake. Another class of drugs are α-glucosidase inhibitors, 
which slow down the absorption of glucose from the intestine. Here, even if the body 
does not produce enough insulin, glucose is absorbed at a slow enough rate where excess 
glucose does not remain (“What I Need”, 2013). 
Researchers have yet to find a cure for type 1 diabetes. Type 2 diabetes, however, 
is mostly reversible, especially if the cause is not genetic. Vigilant monitoring of blood 
glucose levels, as well as diet and exercise go a long way (Zimmet, Alberti, & Shaw, 
11 
 
2001; “Diabetes Care”, 2013). Eating fewer sugar and starch filled foods inherently 
lowers blood glucose levels, and daily exercise burns glucose more readily than a 
sedentary lifestyle. As blood glucose levels return to healthy amounts, many of the 
symptoms associated with type 2 diabetes are likely to diminish in severity (“Diabetes 
Care”, 2013; “Symptoms”, 2013). 
Body of Review: 
 One of the main focuses for researchers now is finding a way for type 1 diabetics 
to produce their own insulin. Filippi and von Herrath hypothesize that pancreatic β cells 
could become injured and unable to produce insulin because of viral-triggered interaction 
(2008). If eventual research can reasonably concluded that viral interactions lead to type 
1 diabetes, then the development of drugs or synthetic/organic materials that blocks viral 
action could possibly lead to the restoration of the pancreatic β cell (or at least the non-
destruction of future pancreatic cells) that could potentially allow the individual to begin 
producing insulin again. 
 Insulin resistance is a common cause for type 2 diabetes (Salway, 2004).  Insulin 
resistance indicates that target cells do not respond appropriately or efficiently to the 
insulin secreted, even if enough insulin is produced by pancreatic β cells. In many cases, 
there is not an appropriate connection made between the insulin and the target receptor 
because of problems with the signaling transduction or defects in the enzymes 
responsible for glucose homeostasis (Salway, 2004). 
 One such problem arises due to the increased inactivation of the insulin receptor. 
Typically, the binding of insulin to the insulin receptor results in the autophosphorylation 
of tyrosine residues in the receptor’s β subunit, which allows insulin signal transduction 
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to start. To stop signal transduction, the receptor becomes dephosphorylated through 
protein tyrosine phosphatase 1b (PTP 1b). Certain individuals have excess PTP 1b 
activity, which prematurely ends insulin signal transduction. Thus, insulin is not 
sufficiently taken up by receptor cells and glucose remains in the blood supply, leading to 
diabetic complications (Salway, 2004). 
 Other molecules potentially involved in the acquisition of type 2 diabetes include 
phosphatidylinositol-3 kinase (PI-3K), PKB, and Glut-4 transporters. PI-3K is part of a 
pathway that promotes the formation of glycogen from glucose. Defects in this molecule 
blocks this pathway and results in excess build-up of glucose. An autosomal dominant 
mutation of PKB has also been shown to exist—this mutation blocks the signal pathway 
that allows for the translocation of Glut-4 to the plasma membrane, which results in 
excess glucose in the blood (Salway, 2004).  
 Insulin inactivity results in the inactivity of cyclic AMP phosphodiesterase-3B 
(PDE-3B). This phosphodiesterase typically removes cyclic AMP, so its inactivity results 
in cAMP build up. This stimulates protein kinase A, which stimulates hormone-sensitive 
lipase (HSL). HSL cleaves triacylglycerols to glycerol and fatty acids, which are used by 
muscle cells more easily than glucose, which leaves more glucose unused in the blood 
supply. Thus, the inactivity of PDE-3B is another signal transduction pathway that leads 
to diabetic symptoms (Salway, 2004). 
 Finally, tumor necrosis factor-α (TNF-α) is thought to play an important role in 
insulin resistance (Hotamisligil & Spiegelman, 1994) TNF-α is associated with Insulin 
receptor substrate-1 (IRS-1), one of the molecules used to relay the signal pathway that 
allows the translocation of Glut-4 to the plasma membrane. IRS-1 associates p85 with PI-
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3K (Salway, 2004), and it is activated by tyrosine phosphorylation and inhibited by serine 
phosphorylation. TNF-α promotes serine phosphorylation, which inhibits IRS-1 and thus 
stops insulin transduction (Hotamisligin & Spiegelman, 1994). This method of insulin 
resistance will be discussed in further detail in the next chapter. 
Conclusion: 
 Diabetic research is important today because of the prevalence of the disease 
within our society. Although more cases of diabetes (type 2) are recorded among older 
individuals, it is a disease that now spans all age groups. A push has already been made 
to promote healthy eating habits and frequent exercise (Zimmet, Alberti & Shaw 2001; 
“Diabetes Care”, 2013) This push needs to continue, and diabetic education should 
continue to become more comprehensive and accessible so that all individuals can know 
pertinent information such as how much exercise is sufficient per day and what foods 
should be enjoyed sparingly (i.e. which foods are high on the glycemic index). Education 
can be used as an adequate technique for prevention when used efficiently.  
 As important as prevention techniques are to avoid the augmentation of the 
diabetic epidemic, it is crucial to address the population already afflicted. Research into 
the methods and mechanisms of insulin resistance is important because it allows a better 
understanding of the disease. This allows for the development of pharmaceuticals and 
surgical techniques that combat the malignancies associated with the disease and mitigate 
any symptoms that might be present. As research into the mechanisms and signaling 
pathways of diabetes continue, it is hoped that the scale of this epidemic reduces in the 






Understanding Molecular Mechanisms—Insulin Receptor Substrate (IRS)-1 
phosphorylation by Tumor Necrosis Factor (TNF)-α induces insulin resistance 
 
Section Overview: 
 TNF-α, a cytokine traditionally viewed as an important effecter in the immune 
system, has recently been identified as a key component in insulin resistance. Typically, 
insulin binding stimulates the tyrosine kinase of the insulin receptor (IR) to 
autophosphorylate the β subunits of the receptor on tyrosine residues, which leads to the 
phosphorylation of insulin receptor substrate (IRS)-1 (Hotamisligil et al., 1996). TNF-α 
promotes the phosphorylation of IRS-1 on serine and threonine residues, which inhibits 
IR from phosphorylating IRS-1 (Stephens, Lee, & Pilch, 1996). TNF-α also inhibits 
tyrosine residue phosphorylation and autophosphorylation of the IR substrate. When IR 
and IRS-1 are not properly phosphorylated, signal transduction does not occur and 
GLUT-4 molecules do not translocate to the cell membrane to uptake glucose molecules. 
Thus, glucose cannot be absorbed even in the presence of excess insulin, leading to 
hyperinsulinemia and hyperglycemia characteristic of insulin resistance and a diabetic 
state (Stephens, Lee, & Pilch, 1996). 
 Mechanistically, TNF-α uses different protein kinases initiating multiple signal 
transduction cascades to lead to insulin resistance. TNF-α induces N-terminal Jun Kinase 
(JNK) to phosphorylate IRS-1 at the Ser307 residue (Rui et al., 2001). Extracellular-signal 
regulated kinase (ERK) and p38 mitogen activated protein kinase (p38MAPK) are also 
used in this mechanism. Protein tyrosine phosphatase (PTP)1B is induced by TNF-α and 
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dephosphorylates the phosphotyrosine residues of the IR and IRS-1 to confer insulin 
resistance (Nieto-Vazquez et al., 2008).  
Introduction: 
TNF-α was originally discovered in bacterially infected animals as an agent 
causing tumor necrosis (Hotamisligil & Spiegelman, 1994). Further research on the 
effects of the cytokine revealed its importance in immune and non-immune systems, 
including the induction of apoptotic cell death, the lysis of tumor cells, the growth of 
thymocytes, and the stimulation of other cytokine production. The cytokine has been 
involved in the propagation and maintenance of certain disease states such as rheumatoid 
arthritis, inflammatory bowel disease and septic shock. TNF-α is associated with 
metabolic diseases as well, such as cachexia or wasting syndrome, which results in 
muscle and fat tissue atrophy (Hotamisligil & Spiegelman, 1994). Within the past two 
decades, TNF-α has also been recognized as a primary contributor to insulin resistance 
(Nieto-Vazquez et al., 2008). 
Insulin resistance is the impaired ability of the cell to respond to the action of 
insulin, and when combined with decreased insulin secretion leads to a pre-diabetic state 
and eventual type 2 diabetes (Nieto-Vazquez et al., 2008). β cells of the pancreas initially 
increase insulin secretion to compensate for the increase in blood sugar levels 
(hyperglycemia) caused by the impaired insulin signaling. Persistent hyperinsulinemia 
and hyperglycemia, however, exacerbates the demand for insulin and results in β cell 
failure and diabetes (Rui et al., 2001; Nieto-Vazquez et al., 2008). As figure 1 indicates, 
insulin resistance also leads to an increase in lipolysis in adipose tissue, which allows free 
fatty acids (FFA) and glycerol to enter the bloodstream. This promotes skeletal muscle 
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insulin resistance and increases gluconeogenesis in the liver. This results in an increase in 
glucose in the bloodstream, which is not taken up by receptor cells because of the 
impaired action of insulin, leaving the body in a state of hyperinsulinemia. Eventually, 
glucose intolerance is observed and diabetes closely follows (Nieto-Vazquez et al., 2008; 
Hotamisligil & Spiegelman, 1994). 
 
 
Figure 1. Type 2 diabetes can be developed from insulin resistance (Nieto-
Vazquez et al., 2008). 
 
 There is a clear link between obesity and the development of insulin resistance as 
well as non-insulin dependent diabetes mellitus (NIDDM). Adipose tissue is recognized 
as a primary contributor to insulin resistance because adipocytes release cytokines, 
chemokines and FFA that impair insulin signaling and alter insulin dependent processes 
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such as lipid metabolism and glucose homeostasis (Nieto-Vazquez et al., 2008). TNF-α is 
considered a linking molecule between the presence of adipose tissue and the 
development of insulin resistance. This is because increased TNF-α expression is found 
in the adipose tissues of obese patients. In fact, circulating levels of TNF-α receptors is 
now well correlated with BMI in patients; an increase in TNF-α is also related to 
increased hyperinsulinemia (Hotamisligil et al., 1996; Nieto-Vazquez et al., 2008). 
Moreover, inhibition of TNF-α processing improves IR signaling and insulin 
sensitivity in peripheral tissues; there is an increase in the uptake of glucose in response 
to insulin (Stephens, Lee, & Pilch, 1996). In mouse models, obese mice lacking the TNF-
α molecule or the receptor showed protection against developing insulin resistance and 
exhibited lower circulating FFA and triglycerides than wild-type animals (Hotamisligil et 
al, 1996; Nieto-Vazquez et al., 2008).  
 
Figure 2. Serine/Threonine phosphorylation of IRS can occur via proteins 
ERK/p38MAPK, whereas tyrosine dephosphorylation occurs using PTP1B (Nieto-
Vazquez et al., 2008). 
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Attention is now turned to deciphering the pathway leading to adipocyte and 
skeletal muscle insulin sensitivity. In a non-insulin resistant state, insulin binds to the α 
subunit of the insulin receptor, which promotes autophosphorylation of the β subunit (Rui 
et al., 2001). This activates the phosphorylation of other cellular substrates, including 
IRS-1. Phosphorylation of multiple tyrosine residues of IRS-1 results is an active 
signaling complex that promotes the transport of the GLUT-4 molecule to the plasma 
membrane (Rui et al., 2001).  Dysregulation of the IR and IRS-1 protein can occur, and 
TNF-α promotes this dysregulation via two different pathways as outlined in figure 2. 
The first mechanism, which will be the primary discussion of this paper, involves 
phosphorylating a serine residue in the 307th position of the IRS-1 molecule. Serine 
phosphorylation inhibits the IR from phosphorylating IRS-1 with tyrosine residues and 
inhibits IR self-phosphorylation as well, which disables IR from binding to IRS-1 and 
prevents proper insulin signaling (Rui et al., 2001). The phosphatase inhibitor okadaic 
acid has been used in previous studies to show the viability of this mechanism: okadaic 
acid causes serine phosphorylation of IRS-1 to inhibit IR signaling (Stephens, Lee, & 
Pilch, 1996; Rui et al., 2001). Rui et al. propose that TNF-α recruits the N terminal Jun 
kinase to phosphorylate the serine residue, whereas Nieto-Vasquez et al. indicate that 
additional kinases—such as IKK and p38MAPK—is utilized by TNF-α as indicated in 
figure 2. 
 The second mechanism involves the upregulation of PTP(1B). PTP(1B) is a 
phosphatase, and inhibits insulin signaling by dephosphorylating the tyrosine residues of 
IRS and the IR (Nieto-Vazquez et al., 2008). By dephosphorylating these residues, the IR 
can no longer bind to IRS and insulin signaling is attenuated. Expression of PTP(1B) is 
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found in increased levels in insulin-resistant states such as obesity, whereas studies with 
PTP(1B) deficient organisms increase their insulin sensitivity and decrease their odds of 
acquiring diabetes (Nieto-Vazquez et al., 2008). Thus, PTP(1B) is an important affecter 
molecule utilized by  TNF-α to maintain resistance to insulin signaling.  
Methods/Results: 
 To confirm the validity of the statement that TNF-α is involved in the 
dysregulation of the IR and IRS-1, adipocytes were cultured with and without the 
presence of TNF-α and the expression of IR, IRS-1 and GLUT-4 were determined 
through gel electrophoresis and immunoblotting using anti-IR, anti-IRS-1 and anti-
GLUT-4 antibodies (Stephens, Lee, & Pilch, 1996; Rui et al., 2001).  
TNF-α downregulates expression of the IR and IRS-1 but does not impact 
phosphorylation: 
 Murine 3T3-L1 pre-adipocytes were primarily used by Stephens et al. After seven 
days in a DMEM and bovine serum medium, it presumed that greater than 95% of the 
cells had differentiated to adipocytes and the cells were harvested and fractionated to 
remove protein content from cell debris (1996). Proteins were separated on a 7 or 12% 
gel and transferred to nitrocellulose membrane after which they were blocked with milk 
and visualized using a horseradish peroxidase-conjugated secondary antibody. Stephens 
et al. used the antibodies R1064 which is generated against the C terminus of the IR to 
detect IR content and used the anti-phosphotyrosine monoclonal antibody 4G10 to detect 
IR phosphorylation. 1F8 was the monoclonal antibody used to determine the insulin-
sensitive GLUT-4 receptor (Stephens, Lee, & Pilch, 1996). 
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 The upper-left blot of figure 3 shows that TNF-α has an inhibitory effect on the IR 
signaling pathway. When compared to 0 hours of TNF-α treatment (the control), 
progressive treatment of TNF-α on adipocytes shows a 30% decrease in IR protein and 
almost 80% decrease in IRS-1 and GLUT-4 expression after 96 hours of TNF-α exposure 
(Stephens, Lee, & Pilch, 1996). SCAMPs, membrane proteins not regulated by TNF-α 
are included in the blot as another control, since change in expression of SCAMPs are 
very minute after TNF-α treatment. The upper-right blot in figure 3 shows the down-
regulation of IRS-1 and GLUT4 mRNA in the presence of TNF-α. β-actin mRNA is 
included in the blot as another control, where TNF-α has no regulation over β-actin 
mRNA expression. The lower blot indicates a negative correlation where the increase in 
concentration of TNF-α results in the decrease in IR expression. The top of the lower blot 
indicates that tyrosine phosphorylation of IR does not occur unless insulin is present, and 
although tyrosine phosphorylation is decreased (since levels of anti-phosphotyrosine 
antibody α-ptyr levels are lower), this is due to the decreased levels of IR itself. Contrary 
to other studies, Stephens et al. seem to suggest that the tyrosine phosphorylation 
mechanism itself is unaffected by the presence of TNF-α. They suggest that TNF-α 
decreases the amount of IRS-1, but the remaining IRS-1 is phosphorylated normally in 






Figure 3. TNF-α shows reduction in the levels of IR, IRS-1, and GLUT-4 expression in 
adipocytes, as well as reduced levels of IRS-1 and GLUT-4 mRNA. TNF-α does not 
change the phosphorylation state of IRS-1 (Stephens, Lee, & Pilch, 1996). 
 
 In the graph in figure 4, the open bars (grey) represent basal levels of tyrosine 
phosphorylation, whereas the black bars represent tyrosine phosphorylation in the 
presence of insulin (Stephens, Lee, & Pilch, 1996). Thus, even in TNF-α treated cells, 
tyrosine phosphorylation occurs to almost the same extent as tyrosine phosphorylation in 
controlled adipocytes (the slight decrease is explained by Stephens et al. as due to the 
reduction in IR substrate). The exogenous tyrosine kinase assay was performed using 
agglutinin-agarose affinity chromatography in the presence of protease and phosphatase 
inhibitors. The radioactivity present in the kinase assay was determined using a 
scintillation counter. The blot in figure 4 shows plasma membrane (PM) and intracellular 
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membrane (IM) levels of GLUT4 in adipocytes in the presence of insulin and TNF-α. 
Cells exposed to insulin only show increase in plasma membrane concentration and 
decrease in insulin membrane concentration of GLUT4, which is expected because 
GLUT4 becomes translocated from the IM to the PM in the presence of insulin. After 
exposure to TNF-α, GLUT4 levels in both the PM and the IM are greatly diminished. 
Thus, Stephens et al propose that not only does TNF-α prevent GLUT4 from being 
translocated from the IM to the PM, TNF-α prevents the transcription of GLUT4 from 




Figure 4. The graph shows that IR phosphorylates tyrosine in an identical mechanism 
whether or not it is treated with TNF- α. The bottom blot shows that GLUT4 
translocation still occurs, although in reduced levels in the presence of TNF-α (Stephens, 
Lee, & Pilch, 1996). 
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TNF-α phoshporylates at Ser307residue of IRS-1 to promote insulin resistance: 
 
 Rui et al. performed similar experiments involving TNF-α induced 
phosphorylation of adipocytes and kidney cells, except these experiments were specific to 
serine phosphorylation on the 307th residue (2001). Rui used very similar methods of cell 
harvesting and immunoblotting as Stephens et al. However, Rui used a different 
antibody, a polyclonal antibody (αpSer307) developed in rabbits against a synthetic 
phosphorylated Ser307 residue based off of the amino acids that surround Ser307. αpSer307 
is effective in specifically recognizing IRS-1 molecules that are phosphorylated at the 
Ser307 residue, as shown in figure 5. Anisomycin is an antibiotic that is shown to activate 
JNK and promote serine phosphorylation to prevent insulin signaling. Figures 5a and 5b 
show that αpSer307 only recognizes IRS-1 protein in adipocytes (5a) and kidney cells (5b) 
when in the presence of Anisomycin. A previous experiment was conducted where Ser307 
in IRS-1 was changed to an alanine by the insertion of a constructed synthetic plasmid. In 
the presence of IRS-1, Anisomycin inhibited tyrosine phosphorylation as expected; 
however, Anisomycin was not able to inhibit phosphorylation of the IRS-1 substrate with 
the SerAla substitution, indicating that the Ser307 residue is crucial in the inhibition of 
IRS-1 phosphorylation. Figure 5d shows that αpSer307 recognizes the SerAla 
substitution as well: whereas αpSer307 binds well to IRS-1 (right lane), αpSer307 






Figure 5. Blots A and B shows Anisomycin stimulated phosphorylation of Ser307, whereas 
Blot D shows the inability of αpSer307 to attach to IRS-1 with an alanine substitution. Blot 
C shows that incubation of αpSer307 with a phosphorylated antigen blocks 
immunoblotting (middle lanes) whereas incubation with an unphosphorylated peptide 
(right lanes) allows immunoblotting to occur. This provides evidence that αpSer307 
indicates the presence of IRS-1 without Tyr phosphorylation residues (Rui et al., 2001). 
 
Figure 6 shows that for both pre-adipocyte (6b) and adipocyte (6c) cells, the 
presence of TNF-α is required for αpSer307 to bind to IRS-1. When the cells are not 
cultured with TNF-α, the αpSer307 antibody does not bind to IRS-1, meaning that there is 
no serine phosphorylation of IRS-1 for the antibody to bind to. Thus, figures 6b &c show 
that TNF-α is required for IRS-1 to become phosphorylated with serine. Figure 6d shows 
that serine phosphorylation occurs almost immediately after the introduction of TNF-α to 
the cell. In this time-course blot, immunoblotting of IRS-1 with αpSer307 occurs within 5 
minutes, indicating that TNF-α begins the mechanism of serine phosphorylating within 
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that time. This mechanism is long lasting as well, with IRS-1 phosphorylated with serine 
residues up to 6 hours after the cell’s original exposure to TNF-α (Rui et al., 2001).  
 
 
Figure 6. Blots B and C show that TNF-α stimulates phosphorylation of IRS-1 on Ser307 
and Blot D indicates this stimulation occurs almost immediately and persists for an 
extended period of time (Rui et al., 2001). 
 
Understanding that insulin signaling is sometimes induced by chronic insulin 
stimulation, Rui et al. performed further experiments to identify whether the presence of 
excess insulin as well as insulin-like growth factor (IGF-1) also caused phosphorylation 
of Ser307 to initiate insulin resistance.  
  
Figure 7. Pre-adipocytes are cultured with 100nM insulin in blot A to induce 
immunoblotting of the IRS-1 substrate to αpSr307 . Blot B shows the immunoblotting of 




Figure 7 indicates that both insulin and IGF-1 (a hormone similar to insulin in molecular 
structure) stimulates the same response in IRS-1 as TNF-α. Blot B indicates that IRS-1 
binds to αpSer307 when insulin or IGF-1 are present, demonstrating that insulin and IGF-1 
enable a mechanism of serine phosphorylation in IRS-1. Blot A indicates that serine 
phosphorylation occurs in IRS-1 within 30 minutes of the addition of insulin to the pre-
adipocytes; the mechanism of serine phosphorylation through insulin can also be 
extended, since IRS-1 substrates maintain almost full levels of serine phosphorylation 
beyond 5 hours. The results from these figures mirror the results gathered from figures 6 
b, c &d, which show that there are similarities between the mechanism of serine 
phosphorylation in TNF-α and phosphorylation by insulin (Rui et al., 2001). 
 Rui et al. engaged in further experimentation to determine whether the serine 
phosphorylation of IRS-1 was present throughout different cells of organisms, not just 
adipocytes (2001). αpSer307 injected into homogenized skeletal muscle of mice resulted in 
the immunoblotting of IRS-1 only in the presence of TNF-α. Rat muscle cells also 
increased serine phosphorylation on IRS-1 substrate by more than a two-fold factor. 
Using a hyperinsulinemic-euglycemic clamp technique (increasing the plasma insulin 
concentration within the body, keeping plasma glucose concentration at basal levels, and 
determining the glucose infusion rate into tissue to determine insulin sensitivity) as well 
as biopsied human muscle, the same results were present in human cells. Thus, the 
prolonged action of insulin indicates the activity of mechanisms that lead to insulin 
resistance in several different organisms (Rui et al., 2001). 
 Rui et al. postulated that two distinct pathways mediated the phosphorylation of 
the Ser307 residue on IRS-1, one pathway utilizing TNF- α signal transduction and the 
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other pathway using insulin signaling (2001). To test this hypothesis, the Akt (protein 
kinase B) and PI-K3 (phosphoinositide kinase) inhibitor LY294002 and wortmannin were 
added to adipocytes incubated with insulin, IGF-1, or TNF- α (figure 8a). As expected, 
the presence of Akt was inhibited when LY294002 and wortmannin were added, but the 
kinase ERK was not. Moreover, IRS-1 immunoblotting by αpSer307 was inhibited in cells 
stimulated by insulin and IGF-1, but immunoblotting occurred normally in cells 
stimulated by TNF- α. Thus, the presence of LY294002 and wortmannin inhibits the 
serine phosphorylation mechanism of insulin, but not the mechanism of TNF- α. Since 
Akt and PI-K3 were also inhibited, Rui proposed that the pathway of Ser307 
phosphorylation of IRS-1 by insulin involved Akt and PI-K3 but probably not ERK.  
Blot B shows that the inhibitor PD98059 blocks IRS-1 immunoblotting by 
αpSer307 when stimulated by TNF- α. Thus, PD98059, which typically inhibits MEK1 
kinase, inhibited the phosphorylation of Ser307 in IRS-1 found in TNF-α stimulated cells, 
leading Rui et al. to believe that PD98059 is involved in the phosphorylating mechanism 
utilized by TNF-α. A separate experiment performed showed that JNK-1 activation was 
not inhibited by PD98059, even though the effectiveness of TNF-α was inhibited. This 
provided doubt as to whether JNK-1 is the main mechanism utilized by TNF-α to 
phosphorylate at Ser307; although it is still believed that JNK-1 is used, it is more 
plausible that a PD98059-sensitive kinase like MEK1 is used by TNF-α instead. Since 
PD98059 does not affect phosphorylation in IRS-1 incubated with insulin, it is assumed 






Figure 8. Blot A shows that the activation of LY29002/Wortmannin inhibits IRS-1 
phosphorylation in insulin and IGF-1 stimulated cells but has no effect on TNF- α 
stimulated cells, whereas blot B indicates that the presence of PD98059 inhibits IRS-1 
phosphorylation in TNF- α stimulated cells but not in insulin or IGF-1 stimulated cells. 
Blot C demonstrates that TNF- α and insulin work synergistically to promote serine 
phosphorylation on IRS-1(Rui et al., 2001). 
 
 Blot C (bottom) provides further evidence that different mechanisms are in place 
in insulin-stimulated and TNF-α-stimulated serine phosphorylation. If the same 
mechanism were used, treatment of cells with both TNF-α and insulin simultaneously 
would not result in an increased Ser307 phosphorylation when compared to the same 
concentration of TNF-α or insulin alone. However, when adipocytes were incubated with 
TNF-α and insulin together, IRS-1 phosphorylation increased dramatically, indicative of 
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synergistic action between TNF-α and insulin from two separate pathways (Rui et al., 
2001).  
Discussion: 
 Stephens et al. concluded that the primary mechanism of TNF-α action was 
through gene expression, which they contend is the general method of action for 
cytokines (1996). They evidence this claim with their results— the presence of TNF-α 
does not show a change in the level of tyrosine phosphorylation in the IRS-1 substrate 
(figure 3). They highlight that although it is evident that TNF-α treatment results in 
decreased concentration of IR, IRS-1 and GLUT4, there is no defect in the actions of the 
molecules. GLUT4 still has the ability to translocate from an intracellular membrane to 
the plasma membrane (although at reduced levels) and tyrosine phosphorylation seems to 
occur normally in the IR and IRS-1 (although tyrosine phosphorylation levels are reduced 
in the presence of TNF-α, this reduction is linear with the concentration of active IR and 
IRS-1). Thus, they hypothesize that TNF-α does not inhibit IR, IRS-1 and GLUT4 
mechanistically, yet instead does so through down-regulation (Stephens, Lee, & Pilch, 
1996). This postulation is evidenced with the blot that shows that TNF-α lowers 
expression levels of IRS-1 and GLUT4 mRNA (figure 3). TNF-α should not have an 
effect on mRNA content if the mechanism of inhibition is phosphorylation of amino acid 
residues to prevent substrate binding and signaling. The reduction of mRNA content 
shows that TNF-α inhibits insulin signaling by reducing the amount of proteins and other 
molecules necessary for the signaling to occur properly and efficiently; it is this genetic 
control that Stephens et al. believe TNF-α promotes to induce insulin resistance (1996).  
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 Several years after the publication of Stephens’ paper, Rui et al. counter that 
TNF-α does in fact use a method of phosphorylation to induce insulin resistance (2001). 
They indicate that a main pathway leading to insulin resistance is through the 
phosphorylation of serine residues in IRS-1, which prevents IRS-1 from binding to the IR 
and reduces insulin signaling within the cell. They originally suspected through previous 
experimentation that TNF-α induced the expression of JNK-1, which bound to IRS-1 to 
phosphorylate the serine residue at the 307th position. They acknowledge that because 
IRS-1 has more than 100 serine residues, it was difficult to identify the specific residue 
that impact IR signaling (Rui et al., 2001). However, after determining Ser307 was in fact 
the residue of interest, they were able to confirm their reasoning when a substitution in 
the 307th position from serine to alanine prevented the phosphorylation in the IRS-1 
substrate (figure 5).  
   
Figure 9. Insulin and TNF-α induce different molecular pathways to phosphorylate the 
Ser307 residue on IRS-1 (Rui et al., 2001). 
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Unexpectedly, Rui et al discovered that insulin had the ability to phosphorylate at 
Ser307, thus also inducing insulin resistance (2001). They considered this as a mechanism 
of feedback inhibition, where the presence of chronic hyperinsulinemia induces insulin 
resistance to mitigate the hormonal effects of insulin throughout the body. Through the 
use of inhibitors LY294002, PD98059 and Wortmannin (figure 8), they were able to 
discover that at least two different pathways exist to phosphorylate the Ser307 residue of 
IRS-1. 
Figure 9 illustrates these pathways: A PI-K3 kinase is utilized by insulin and IGF-
1 to phosphorylate the serine residue. Whereas it was originally thought that JNK-1 was 
used by TNF-α to serine phosphorylate, PD 98059 did not inhibit JNK-1 action, although 
it did inhibit serine phosphorylation in TNF-α incubated cells. Rui et al believe that JNK-
1 is still used in the pathway, but they believe that another PD98059 sensitive kinase like 
MEK-1 or ERK must be used as well. Because these pathways are distinctly separate, 
stimulation by TNF-α and insulin can occur concurrently to upregulate phosphorylation 
of Ser307 at levels beyond the action of TNF-α or insulin alone. If inhibitors LY294002, 
PD98059 and Wortmannin decrease levels of serine phosphorylation, and it has been 
shown that phosphorylation at Ser307 inhibits IRS-1 interaction with IR to induce insulin 
resistance, then future research exists to determine whether these inhibitors can be used 
with pharmaceuticals to alleviate the effects of insulin resistance (Rui et al., 2001).  
 Nieto-Vazquez et al. compiled research to determine that IRS-1 phosphorylation 
at serine residues could occur through mechanisms involving other cytokines as well 
(2008). Obesity has recently been described as a state of low-level chronic inflammation, 
so it is not surprising that insulin resistance (which is strongly correlated with obesity) 
32 
 
has been associated with one of the pro-inflammatory kinases p38MAPK (Nieto-Vazquez 
et al., 2008). Experimentation showed that muscle cells exposed to TNF-α produced 
phosphorylation of p38MAPK; moreover, inhibition of p38MAPK in TNF-α incubated 
cells completely restored insulin stimulated glucose uptake and insulin signaling. IkB 
kinase (IKK) is another pro-inflammatory enzyme that is possibly utilized by TNF-α to 
induce serine phosphorylation; research shows that the inhibition of IKK activity leads to 
insulin signaling restoration, despite the presence of TNF-α. Nieto-Vazquez et al. agree 
that ERK and JNK-1 are used in molecular mechanism triggered by TNF-α to induce 
serine phosphorylation, but they imply that these additional cytokines, IKK and 
p38MAPK, are also crucial for sufficient signaling by TNF-α to take place (Nieto-
Vazquez et al., 2008). 
 Both Rui and Nieto-Vazquez agree upon TNF-α inducing serine phosphorylation 
of IRS-1 being an important step in the mechanism to prevent insulin signaling; another 
important step reportedly mediated by TNF-α is the inhibition of the autophosphorylation 
of the IR and the tyrosine phosphorylation of the IRS-1 substrate. TNF-α was identified 
to decrease levels of autophosphorylation in the insulin receptor; it was also noted that 
TNF-α decreased levels of tyrosine residue phosphorylation in IRS-1, which was 
suspected to be due to increased levels of serine phosphorylation in IRS-1 (Hotamisligil 
et al., 1996; Hotamisligil & Spiegelman, 1994). Nieto-Vazquez et al. posit that TNF-α 
reduces tyrosine phosphorylation in IRS-1 through the use of the phosphatase PTP(1B). 
Adipocytes treated with TNF-α show an increase in PTP(1B) mRNA and PTP(1B) 
protein activity; conversely, the inhibition of PTP(1B) provides protection against TNF-α 
insulin resistance (Nieto-Vazquez et al., 2008). PTP(1B) expression has been elevated in 
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pathological states strongly correlated with insulin resistance such as obesity, and over-
expression of this protein is also associated with reduced GLUT4 function and glucose 
uptake in tissue. In mice models, PTP(1B) over-expression caused insulin resistance, 
whereas the deficiency of this protein allowed insulin sensitivity to return as quickly as 
12 hours (Nieto-Vazquez et al., 2008).  
 Recent research in this topic concurs that PTP(1B) is utilized by TNF-α as part of 
a mechanism to induce insulin resistance. Stephens’ and Rui’s research overlooks this 
molecule most likely because the effects of PTP(1B) was not widely known when their 
research was conducted. Thus, it is plausible that the mechanisms of insulin resistance 
induced by TNF-α that Stephens and Rui outline in their research (which is presented in 
this paper) can very well likely incorporate PTP(1B) as an effecter molecule.  
 As diabetes and insulin resistance has recently become widespread, clinical 
advancements to discover pharmaceutical agents that block the mechanisms of insulin 
resistance or promote insulin signaling are greatly sought out (Nieto-Vazquez et al., 
2008). Nuclear receptors such as liver X receptor (LXR) have been promising: nuclear 
receptors are agonists for PPARγ (peroxisome proliferator activated receptor, a receptor 
that aids in adipogenesis). Nuclear receptors thus decrease hyperglycemia by inducing the 
formation of lipids from free floating sugars, yet keep insulin levels from rising as well to 
prevent insulin resistance. LXR has also been shown to regulate GLUT4 expression, 
where upregulation of GLUT4 decreases hyperglycemia.  Thiazolidinediones (TZDs) 
have had success in treating type 2 diabetes as well; TZDs increase the expression of the 
IR and of IR tyrosine kinase activity (thus promoting tyrosine phosphorylation). TZDs 
have also impaired the activity of p38MAPK and ERK, thus preventing TNF-α from 
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phosphorylating at serine residues in IRS-1 and preventing insulin desensitization (Nieto-
Vazquez et al., 2008). 
 Skeletal muscle actually uses AMP activated protein kinase (AMPK) to promote 
GLUT4 translocation to the plasma membrane. AMPK is insulin independent and is 
activated by stimuli such as exercise or hypoxia (reduced oxygen supply). Even in 
diabetic patients, studies have shown that the level of GLUT4 translocation due to 
contraction stimulation (i.e. the AMPK pathway) was similar to that of a non-diabetic 
control group. This would mean that hyperglycemia could be avoided and the persistence 
of chronic hyperinsulinemia would be lessened. Thus, regular exercise has the possibility 
to mask the deleterious effects of insulin resistance partially caused by the overexposure 
of cytokines such as TNF-α (Nieto-Vazquez et al., 2008). Type 2 diabetics now have 















Type 2 Diabetes Mellitus: A Clinical Case Study 
Patient Introduction: 
ID: 
Ileana Hermosa is a 35 y.o Hispanic female. 
CC: 
“Using the bathroom often throughout the day and always feeling thirsty” 
Patient History: 
History of Present Illness (HPI): 
Ileana Hermosa came into the clinic with complaints of polydipsia (excessive 
thirst) and polyuria (excessive urination) (“Symptoms”, 2013). These symptoms have 
been recurring for the past 3-4 weeks, but Ms. Hermosa has not been able to receive 
medical care until now because of her job schedule. She states that she needs to use the 
restroom more than 4 times a night during some nights (nocturia), which affects her sleep 
as well. She states that this has made her even more fatigued while she works, although 
she admits that she has had more bouts of fatigue over the past 6 months than she has 
before in adulthood.  
She believes that her increased fatigue has caused her overall health to decrease as 
well. She has had persistent yeast infections over the past 1.5 months and has received 
medication about 1 month before that she still uses today because the infection has not 
gone away. She has itchiness and tenderness in the vagina. 
She is constantly feeling thirsty as well. At first, she believed she was getting sick 
with the flu, as thirst and a sore throat has always been the first sign for her that she was 
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catching the cold, but after 1 week of no other symptoms of the flu (i.e. runny nose, 
cough, fever), she realized that this thirst was due to something else. She now brings 2-
liter bottles of water to work, whereas 20 oz. would suffice in the past. 
Ms. Hermosa has not felt any other pain in her body, nor has she had any serious 
complications manifest with any of her complaints. She just believes that her symptoms 
are an annoyance that will not let her “carry on with life normally” (“Symptoms”, 2013). 
Past Medical History: 
 Medications:  
o Monistat—used for Candidiasis (Yeast Infection) (“Candidiasis”, 2014) 
o Birth Control 
 Previous Surgeries 
o Caesarian Section for 2nd birth 6 years ago (son in breech position) 
 Allergies 
o No known drug allergies 
 Immunizations 
o All are current 
Family History: 
 2 maternal uncles have Type 2 Diabetes Mellitus (TIIDM); paternal grandfather 
had TIIDM before death 




 Mother and father both have dyslipidemia (high blood cholesterol); maternal 
uncles with TIIDM also present with dyslipidemia; pt does not know if she has 
it—has not been tested in 3+years (“Genetics of Diabetes”, 2013) 
 Maternal grandmother had end stage renal failure 
 Mother and 2 maternal uncles are obese; paternal grandfather and grandmother 
obese as well 
Social History: 
 Marital Status: separated from husband for past 3 months; married 11 years 
beforehand 
 Sexual History: not currently sexually active for 3 months, previously active; 
currently still on birth control 
 Living Situation: In a house with 2 children; husband lives 20 min away in an 
apartment and takes children on weekends 
 Alcohol: previously social drinker; none for 2+ years 
 Tobacco: denies use 
 Illicit Drugs: denies use 
 Caffeine: 1 cup of coffee per day in mornings; soft drinks almost every day 
 Diet: traditional Hispanic foods, high in fat and calories; frequents fast food; 
processed and frozen meals as well 
 Exercise: work (manual labor in food processing plant); chores around house and 
picking up after children; does not go to gym or do intentional exercise 
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Review of Systems (“Symptoms”, 2014; “History & Physical”, n.d.): 
 Constitutional: very fatigued and slight weakness; no weight loss, fever, or 
chills 
 HEENT: 
o Head: slight headaches; no dizziness or neck pain 
o Ears: no loss of hearing, no ear infections; no tinnitus 
o Eyes: no loss of vision acuity; no dryness, redness or infection 
o Nose: no runny nose, sneezing, or congestion;  
o Throat: sore throat and dryness due to polydipsia 
 Cardiovascular: no chest pain, chest pressure or chest discomfort; no palpitations 
or edema 
 Respiratory: no shortness of breath, cough, or sputum 
 Gastrointestinal: no diarrhea, vomiting, or indigestion;  
 Genitourinary: polyuria; vaginal puritis; last menstruation 3 months ago; no 
history of STDs  
 Musculoskeletal: no muscle, back, or joint pain; slight soreness in movements 
 Integumentary: no cyanosis, jaundice, or redness; no rashes, wounds or lesions 
 Neurological: no headache, dizziness, syncope, or ataxia; no numbness or tingling 
in extremities 
 Psychological: increased anxiety and slight depression since separation with 





 Vitals (“History & Physical”, n.d.; “Diabetes Mellitus”, 2013): 
o Height: 5’ 4” 
o Weight: 225 lbs 
o BMI: 38.6 
o Temperature: 98.8 ˚F 
o Respirations: 16 breaths 
o Blood Pressure: 140/96 mmHg (rechecked: 142/94 mmHg) 
o Pulse Oximetry: 97% saturation in room air 
o Pulse: 86 bpm  
 General: 35 y/o obese female who is awake and alert; obese; appears fatigued and 
anxious 
 HEENT: 
o Head: atraumatic/normocephalic; no tenderness in frontal, ethmoid or 
maxillary sinuses; no tenderness in temporomandibular joint 
o Eyes: PERRLA (pupils equally round and reactive to light and 
accommodation), EOMI (extraocular muscles intact), conjunctiva clear 
and non-icteric 
o Ears: clear, bilateral tympanic membrane intact and reactive to light, no 
signs of inflammation; shape is normal 
o Nose: no septal deviation, no nasal polyps, no unusual discharge or 
swelling; shape is normal 
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o Throat/Oral: mucous membranes dry, dentition intact, no visible caries; 
no exudates or erythema; tonsil size 1+ 
 Neck: supple, no thyromegaly, no jugular veinous distention, no 
lymphadenopathy, no carotid bruit, trachea is midline 
 Chest: no wheezing, rales, or rhonchi upon auscultation; no egophony, normal 
percussion, no respiratory distress 
 Heart: regular rate and rhythm; normal S1 and S2; no rubs, gallops, murmurs, or 
thrills; non-displaced point of maximal impact (PMI); no orthostatic hypotension 
 Abdomen: obese, with mostly visceral adiposity; no tenderness upon palpation; 
normal bowel sounds in four quadrants; no spasms; no hepatomegaly, nodularity 
or masses; no splenomegaly 
 Genitourinary: redness and swelling present in vulva, vagina, and cervix; 
small amount of white discharge; no masses or lesions, no adnexal tenderness, 
internal os of cervix closed 
 Rectum: good tone, non-tender, no palpable masses 
 Back: no costovertebral angle tenderness (CVAT), no spasms, kyphosis, or 
scoliosis 
 Extremities: full range of motion with 5+ strength in all extremities; no clubbing, 
cyanosis, or edema (C/C/E); 2+ pulse at dorsalis pedis and posterior tibial 
 Skin: loss in turgor; no jaundice, cyanosis, or redness; no rashes or lesions 
 Neurological: cranial nerves II-XII intact, no facial droop; no nystagmus or 
clonus; normal responses to all reflexes; normal responses to stimuli; speech is 
clear, patient is appropriate and cooperative 
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 Mental Status: alert and oriented x 3 (“History & Physical”, n.d.; “Diabetes 
Mellitus”, 2013) 
Diagnostic Work: 
Lab values were retrieved from “Normal Lab Values” from Marshall University 
School of Medicine (n.d.), “Normal Lab Values” from University of Minnesota (2006), 
“Symptoms” from the ADA (2013), “Management of Dyslipidemia” from the ADA 
(2013) and “The A1C test” from the National Institute of Diabetes (2013). 
Complete Blood Count (CBC):    Reference Ranges: 
RBC Count: 5.0 x 106 cells/μL    (4.2-5.9 x 106 cells/μL) 
Hemoglobin: 13.5 g/dL     (12-16 g/dL) 
Hematocrit: 44%      (36-47%) 
MCH: 30 pg       (28-30pg) 
MCHC: 37 g/dL      (32-36 g/dL) 
MCV: 85 fL       (80-100 fL) 
Platelet Count: 250,000/μL     (150,000-350,000/μL) 
WBC Count: 8,800 cells/μL     (4000-10,000 cells/μL) 
Automated Differential WCC 
Neutrophils: 60%       (40-75% of WBCs) 
Lymphocytes: 32%      (20-45% of WBCs) 
Monocytes: 5%      (2-10% of WBCs)  
Eosinophils: 3%      (1-6% of WBCs) 
Basophils: 0.4%      (0-1% of WBCs) 
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Comprehensive Metabolic Panel: 
Albumin: 4.2 g/dL      (3.5-5.5 g/dL) 
Alkaline phosphatase: 48 U/L    (36-92 U/L) 
ALT: 11 U/L       (0-35 U/L) 
AST: 14 U/L       (0-35 U/L) 
BUN: 14 mg/dL      (8-20 mg/dL) 
Calcium: 9.9 mg/dL      (9-10.5 mg/dL) 
Creatinine: 1.1 mg/dL      (0.7-1.3 mg/dL) 
Glucose: 278 mg/dL      (70-100 mg/dL) 
Total bilirubin: 0.7 mg/dL     (0.3-1.2 mg/dL) 
Total protein: 7.0 g/dL     (6.0-7.8 g/dL) 
Electrolytes: 
Sodium: 140 mmol/L       (136-145 mmol/L) 
Potassium: 4.3 mmol/L     (3.5-5.0 mmol/L) 
Chloride: 103 mmol/L     (98-106 mmol/L) 
Bicarbonate: 24 mmol/L     (23-28 mmol/L) 
 
Lipid Panel: 
Cholesterol: 331 mg/dL      (less than 200 mg/dL) 
Triglycerides: 289 mg/dL      (less than 150 mg/dL) 
HDL: 27 mg/dL      (greater than 60 mg/dL) 
LDL: 192 mg/dL      (less than 130 mg/dL) 




Appearance: Clear, Pale     Clear, Pale 
Bilirubin:  Negative      Negative 
Blood: Negative      Negative 
Ketones: Negative      Negative 
Glucose: Positive      Negative 
Leukocytes: Negative      Negative 
Protein: Negative      Negative/Trace 
Nitrite: Negative      Negative 
Squamous Epithelial Cells: Negative    Negative 
Specific Gravity: 1.028     (1.002-1.030)    
pH: 5.4       (5.0-7.0) 
Urine Microscopic Exam: 
RBC: 0/HPF       (0-2/HPF) 
WBC: 0/HPF       (0-2/HPF) 
RBC Cast: 0/HPF      (0/HPF) 
 
Hemoglobin A1c 
HbA1c: 9.6%       (less than 5.6%) 
 
Thyroid Functions Test 
Serum thyroxine (T4): 8 μg/dL    (4.6-12 μg/dL) 
Free thyroxine (FT4): 1.2 ng/dL    (0.7-1.9 ng/dL) 
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Serum triiodothyronine (T3): 134 ng/dL   (80-180 ng/dL) 
Serum thyrotropin (TSH): 2.2 μU/mL   (0.5-6.0 μU/mL) 
 
Pregnancy 




 Diabetes Mellitus: hyperglycemia 
 Vaginitis: redness and swelling in vulva, vagina, and cervix; white discharge 
 Hypertension: blood pressure 140/96 
 Dyslipidemia: high cholesterol, high triglycerides, high LDL, low HDL 
Differential Diagnosis: 
 Diabetes Mellitus: hyperglycemia, polydipsia, polyuria, fatigue, vaginitis; 
correlated with obesity, dyslipidemia, and hypertension 
 Urinary Tract Infection: polydipsia 
 Pregnancy: polydipsia, polyuria, dehydration, fatigue, menstrual irregularity 
 Hypothyroidism: fatigue, obesity, menstrual irregularity 
Discussion:  
 This is a 35 year-old obese female presenting with polyuria, fatigue, 
hyperglycemia, and polydipsia. Given this constellation of symptoms, the patient is most 
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likely suffering from diabetes mellitus type 2 (“Symptoms”, 2013). A urinary tract 
infection (UTI) is unlikely because the urinalysis was negative for everything except for 
glucose. If the patient had a UTI, the urine would be cloudy, and traces of blood and 
protein would be present to indicate kidney infection/damage (“Urinary Tract”, 2014). 
Pregnancy is ruled out because the pregnancy test was negative. Hypothyroidism is also 
unlikely given that her thyroid function test (TFT), including TSH, was within normal 
limits. TSH levels over 6.0 μU/mL as well as T3 levels below 80 ng/dL or free T4 levels 
below 0.7 ng/dL are indicative of hypothyroidism (“Hypothyroidism”, 2014). 
 With a positive fasting glucose level above 126 mg/dL and a Hemoglobin A1c 
above 6.5%, the patient can be diagnosed with diabetes mellitus. Polydipsia and polyuria 
are often associated with and usually are the first signs of diabetes, which leads to 
dehydration (explaining the loss of skin turgor and dry mucous membranes). Moreover, 
diabetics more easily fatigued and more susceptible to infection (hence the prolonged 
duration of the Candidiasis). Although not symptoms, obesity, dyslipidemia, and 
hypertension are strongly correlated with diabetes. Moreover, the family history of 
TIIDM pre-disposes the patient to acquiring the disease (“Symptoms”, 2013). 
Prognosis 
Ms. Hermosa is diagnosed with TIIDM. TIIDM is quite common in the United 
States, with over 24 million people diagnosed and accounting for over 90% of all diabetic 
patients (“Diabetes Data”, 2013). TIIDM results because of insulin resistance and 
defective insulin secretion. The consequence is a continual state of hyperglycemia. 
TIIDM can be treated with medication that reduces blood glucose levels; as Ms. Hermosa 
becomes less hyperglycemic, the symptoms that she presents with—such as polydipsia, 
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polyuria, and fatigue—will reverse and subside away. If left untreated, TIIDM has 
harmful consequences and can lead to microvascular and macrovascular damage 
(Zimmet, Alberti & Shaw, 2001). 
On the macrovascular level, there is a strong correlation between cardiovascular 
disease and diabetes, with over 65% of diabetics dying from heart disease and stroke. In 
fact, diabetics are twice as likely to develop CVD as normal adults.  There is a strong 
correlation between TIIDM and obesity (specifically visceral obesity) and with obesity-
associated diseases such as hypertension and dyslipidemia. All of these are risk factors 
for cardiovascular disease, especially coronary artery disease (build up of plaque in 
arteries) and congestive heart failure (inability to pump blood effectively) (Zimmet, 
Alberti & Shaw, 2001). 
Speaking to microvascular damage, other consequences include diabetic 
retinopathy, which is the damage of blood vessels supplying the retina. Diabetic 
retinopathy is a major cause of blindness in American adults (“Facts about Diabetic”, 
2012). The tingling and numbness that is often associated with diabetes is due to diabetic 
neuropathy, which is damage to nerves, especially in the extremities. Neuropathy, along 
with peripheral arterial disease, leads to decreased blood flow, increased likelihood of 
infection and ulcers in the extremities; this sometimes leads to amputations to remove 
necrosis (Boulton, Gries, & Jervell, 1998). Uncontrolled TIIDM can also develop kidney 
disease, immunosuppresion leading to an increased risk of infection and poor wound 






Diabetes Mellitus:  
Biguanides are a class of drugs that increase insulin sensitivity in peripheral tissues while 
decreasing glucose production in the liver (“Medication”, 2014). Metformin is a 
commonly used biguanide; Ms. Hermosa will be prescribed 500 mg Metformin once a 
day. She will be given a blood glucose meter and told to journal her food intake. It will be 
expected that she follow a more balanced diet with fewer carbohydrates and cholesterols 
while increasing her fruit and vegetable intake. She will be given information on a 
diabetic diet. A follow up visit will be scheduled 3 months later. If hyperglycemia is not 
better controlled (if there is not a drop in the Hemoglobin A1c by 1-2 percentage points), 
there will be a discussion with the patient about adding a second drug and if so, she will 
be prescribed 2 mg of Amaryl per day in addition to the Metformin. Amaryl is a 
sulfonylurea that stimulates beta cells of the pancreas to produce insulin to increase 
serum insulin levels. Another follow up will be scheduled in 3 months to track progress 
(“Medication”, 2014). 
Vaginitis:  
Ms. Hermosa will still be instructed to use Monistat for the vaginitis. Monistat is an anti-
fungal that kills the Candida albicans yeast that causes the yeast infection (“Candidiasis”, 
2014).  If vaginitis persists in the following week, oral fluconazole 150 mg (standard 
dose) will be prescribed. Fluconazole is an anti-fungal that kills Candida albicans by 
inhibiting the production of ergosterol, a sterol that is essential for the yeast’s cell 





Statins can be prescribed to lower cholesterol and triglyceride levels. Statins inhibit the 
enzyme HMG-CoA reductase, which prevents the formation of cholesterol. Statins can 
mildly increase HDL levels as well. Lipitor (atorvastatin) at 20 mg per day will be 
prescribed to Ms. Hermosa to combat dyslipidemia. A balanced diet and exercise will 
also help Ileana lower cholesterol levels (“Management of Dyslipidemia”, 2014). 
Hypertension:  
ACE inhibitors (angiotensin-converting-enzyme inhibitors) prevent the conversion of 
angiotensin I to angiotensin II in the renin-angiotensin aldosterone system, which dilates 
blood vessels and lowers blood volume to decrease blood pressure. ACE inhibitors have 
been shown to be protective against renal microvascular damage in diabetics. Ms. 
Hermosa will be prescribed 10mg of lisinopril a day. If blood pressure does not decrease 
at the follow-up visit, dosage will be increased to 20 mg per day (Neal, 2000). 
Plan Implementation: 
Ms. Hermosa will be advised to attend diabetes support groups, obesity support 
groups, and community nutrition wellness courses (“Diabetes Mellitus”, 2013). Nutrition 
courses will allow Ms. Hermosa to understand which foods to avoid, which to eat in 
moderation, and which are “safe” and will not cause glycemic spikes. Dieticians can 
explain to her what carbohydrate choices are and how many can be included in balance 
meals. Diabetic support groups can provide guidance, encouraging her to continue 
logging glycemic levels using the blood glucose monitor; these groups will encourage her 
to maintain healthy lifestyle patterns, and will inform her of the negative consequences of 
leaving TIIDM uncontrolled (“Diabetes Mellitus”, 2013). 
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Ms. Hermosa is psychologically/emotionally fragile because of the recent 
separation from her husband. This can cause her to stress-eat and stray away from a 
healthy exercise and diet routine. It is thus important that Ms. Hermosa receive 
counseling to cope with anxiety from the separation and still be able to commit to the 
stress of making the drastic lifestyle changes needed to maintain good health. 
Some diabetic groups offer resources (such as free glucose monitors and test 
strips) which can mitigate the financial burden. At first, pharmaceutical costs might be 
high. However, if Ms. Hermosa follows the treatment plan appropriately, many of her 
symptoms will lessen in severity and her blood glucose levels, lipid levels, and blood 
pressure can return to normal values. This reduces the number of medicines she has to 
purchase, also mitigating cost (“Diabetes Mellitus”, 2013). Finally, the implementation of 
the Affordable Care Act requires everyone to be insured; having healthcare insurance 
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